[ad_1]

Wegovy injection pens

A medical path discovered that Wegovy may minimize the chance of great coronary heart occasions by 20%
Picture: Employees (Reuters)

Medicare will begin masking the favored weight reduction drug Wegovy for sufferers who’re prescribed the treatment as a method to cut back their threat of great coronary heart occasions akin to coronary heart assaults and strokes, the U.S. Facilities for Medicare and Medicaid Companies (CMS) introduced on Thursday.

“CMS has issued steerage to Medicare Half D plans stating that anti-obesity drugs that obtain FDA approval for a further medically accepted indication might be thought of a Half D drug for that particular use,” a CMS spokesperson told Reuters in an emailed statement.

The brand new steerage comes a few week after federal regulators expanded the accepted use of Wegovy to incorporate lowering coronary heart dangers for adults who’re overweight or obese.

The extremely coveted treatment belongs to the identical class of drug as diabetes treatment Ozempic, which can also be recognized for its weight reduction unintended effects.

The U.S. Meals and Drug Administration (FDA) expanded the approved use of Wegovy on March 8, months after its maker Novo Nordisk introduced outcomes from a medical trial that discovered the drug cut the risk of serious heart events by 20%.

Ozempic — additionally produced by Novo Nordisk — is already lined by Medicare.

Wegovy provide remains to be behind

The information may make it tougher for sufferers to fill their prescriptions, as Novo Nordisk has had a troublesome time assembly skyrocketing demand for the drug. Since Could 2023, Novo Nordisk has been limiting starter doses to make sure there may be sufficient provide for sufferers already on the drug.

The corporate introduced in February that in an effort to deal with a scarcity of Wegovy, it acquired three facilities from its firm’s largest shareholder Novo Holdings for $11 billion. The deal was made in reference to Novo Holdings’s acquisition of the drug manufacturing firm Catalent.

Novo Nordisk mentioned in a press release that the acquisition will improve the corporate’s manufacturing capability from 2026 and onwards.

[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *